New hope for men with advanced prostate cancer: enzalutamide delays cancer growth
NCT ID NCT02294461
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tested the drug enzalutamide in 395 men with advanced prostate cancer that had spread and was no longer controlled by standard hormone therapy. Participants had not yet received chemotherapy. The goal was to see if enzalutamide could delay the rise of PSA levels, a marker of cancer progression, compared to a placebo. The results help doctors understand how to better manage this stage of prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CN00102
Shanghai, China
-
CN00103
Beijing, China
-
CN00104
Beijing, China
-
CN00105
Shanghai, China
-
CN00106
Beijing, China
-
CN00107
Hangzhou, China
-
CN00108
Shanghai, China
-
CN00109
Wuhan, China
-
CN00110
Nanjing, China
-
CN00111
Beijing, China
-
CN00112
Beijing, China
-
CN00113
Shanghai, China
-
CN00114
Beijing, China
-
CN00115
Beijing, China
-
CN00117
Nanjing, China
-
CN00118
Wenzhou, China
-
CN00119
Suzhou, China
-
CN00121
Changsha, China
-
CN00124
Xi'an, China
-
CN00125
Tianjin, China
-
CN00126
Shanghai, China
-
CN00127
Beijing, China
-
HK00402
Hong Kong, Hong Kong
-
KR00201
Incheon, South Korea
-
KR00202
Seongnam-si, South Korea
-
KR00203
Daegu, South Korea
-
KR00204
Seoul, South Korea
-
KR00205
Busan, South Korea
-
KR00206
Seoul, South Korea
-
KR00207
Busan, South Korea
-
KR00208
Seoul, South Korea
-
KR00209
Seoul, South Korea
-
KR00210
Seoul, South Korea
-
KR00211
Seoul, South Korea
-
KR00212
Cheongju-si, South Korea
-
KR00213
Daejeon, South Korea
-
KR00214
Anyang, South Korea
-
KR00215
Seoul, South Korea
-
TW00301
Taipei, Taiwan
-
TW00302
Taichung, Taiwan
-
TW00303
Taichung, Taiwan
-
TW00304
Taipei, Taiwan
-
TW00305
Taoyuan County, Taiwan
-
TW00306
Taipei, Taiwan
-
TW00307
Tainan, Taiwan
-
TW00308
Tainan, Taiwan
-
TW00309
Kaohsiung City, Taiwan
Conditions
Explore the condition pages connected to this study.